Side-by-side · Research reference

ProstamaxvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BFDA-ApprovedFlagship14/45 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Prostamax

Tirzepatide

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Tirzepatide

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

Indefinite for chronic indication

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

Reconstitution

—

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

—

Once weekly, any time of day

Half-life

—

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

04Side Effects & Safety

Parameter

Prostamax

Tirzepatide

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

Contraindicated

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

Prostamax

Tirzepatide

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

Pen-supplied. Research vial: 27–31G insulin syringe.